| Baseline | Sixth month | ||||||
---|---|---|---|---|---|---|---|---|
All participants | Placebo group | Low-dose group | High-dose group | All participants | Placebo group | Low-dose group | High-dose group | |
ALT | 9.72 ± 3.60 | 10.17 ± 4.04 | 9.63 ± 3.12 | 9.37 ± 3.65 | 16.82 ± 12.70 | 17.05 ± 9.97 | 17.09 ± 17.67 | 16.13 ± 6.54 |
AST | 15.48 ± 3.40 | 15.93 ± 3.18 | 15.30 ± 3.04 | 15.20 ± 3.96 | 17.37 ± 6.34 | 16.62 ± 5.08 | 17.78 ± 7.94 | 17.75 ± 5.48 |
UA | 345.58 ± 89.29 | 342.90 ± 83.96 | 328.40 ± 88.22 | 365.43 ± 94.42 | 333.10 ± 70.49 | 322.52 ± 62.01 | 343.48 ± 80.41 | 332.06 ± 67.91 |
BUN | 3.77 ± 2.63 | 4.03 ± 4.42 | 3.61 ± 0.82 | 3.66 ± 0.93 | 4.65 ± 1.15 | 4.61 ± 1.01 | 4.74 ± 0.99 | 4.57 ± 1.55 |
CA125 | 19.63 (15.21–26.75) | 19.62 (15.19–25.54) | 19.36 (14.65–30.49) | 20.75 (15.36–31.66) | 15.13 (9.87–19.72) | 15.85 (9.65–20.39) | 13.18 (9.07–18.53) | 15.13 (9.45–22.67) |
CA153 | 13.21 (10.56–16.07) | 13.20 (10.70–16.87) | 12.81 (10.78–16.32) | 13.39 (9.68–15.76) | 8.62 (6.55–12.30) | 7.52 (6.27–11.86) | 8.89 (6.41–12.44) | 10.49 (7.33–12.44) |
CA199 | 9.54 (6.91–14.48) | 9.29 (6.38–15.42) | 8.66 (7.03–19.38) | 10.27 (7.03–14.47) | 9.11 (6.48–14.45) | 10.58 (6.13–15.45) | 7.53 (6.53–15.76) | 10.78 (6.42–14.13) |
CEA | 0.62 (0.31–0.87) | 0.70 (0.30–0.85) | 0.60 (0.38–0.90) | 0.61 (0.21–0.83) | 0.84 (0.53–1.48) | 1.21 (0.54–1.59) | 0.66 (0.51–1.39) | 0.79 (0.60–1.38) |